SBRA
Sabra Healthcare REIT Inc
19.20$
-0.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +0.1% | -0.2% | -0.4% | +0.3% | -1.2% | -1.3% | +1.8% | +4.4% | -1.3% | +1.8% | -1.4% | |
| – | -1.6% | -60.6% | -12.1% | -38.8% | +71.7% | -21.6% | +65.3% | +25.0% | -40.9% | -34.8% | +193.0% | |
| – | +24.1% | +45.2% | -39.3% | +73.1% | -4.0% | -62.5% | +320.1% | +110.8% | -64.3% | +72.6% | +87.6% | |
| – | +24.1% | +45.2% | -39.3% | +73.1% | -4.0% | -62.5% | +320.1% | +110.8% | -64.3% | +72.6% | +87.6% | |
| – | -3.3% | -70.1% | -1.5% | -16.9% | +8.5% | -4.1% | +22.7% | -27.0% | -1.7% | +33.1% | -12.2% | |
| – | +5.1% | +28.3% | +459.3% | -79.4% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -0.7% | – | – | – | – | |
| – | -5.7% | -8.4% | -2.0% | +3.9% | -4.6% | -9.6% | -0.7% | +142.6% | +9.2% | +3.2% | +23.1% | |
| – | +2.9% | +0.9% | -0.7% | +1.2% | -2.2% | -1.2% | +3.4% | +4.6% | -2.5% | +5.0% | -1.5% | |
| – | +80.0% | +11.9% | -56.4% | +1.6% | +95.8% | -49.4% | +7.3% | +1.7% | +171.6% | -97.4% | -7.1% | |
| – | +18,823.6% | +54.7% | -99.3% | -49.9% | +20,670.8% | -98.5% | +463.0% | -8.2% | +2,577.3% | -95.9% | -87.9% | |
| – | -5.8% | -20.0% | +91.1% | -36.8% | – | – | – | – | – | – | – | |
| – | +0.1% | -0.1% | +5.6% | +1.0% | -6.4% | +3.6% | +3.6% | +4.5% | -10.8% | 0.0% | -0.1% | |
| – | -2.3% | -1.3% | -0.2% | -0.6% | -0.1% | -1.4% | +0.3% | +4.2% | -0.1% | -1.3% | -1.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.9% | +0.1% | +0.2% | +1.4% | +1.1% | +0.3% | +0.3% | +1.1% | +3.8% | +1.3% | -1.4% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.